GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Total Stockholders Equity

Bio-Techne (Bio-Techne) Total Stockholders Equity : $2,014 Mil (As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Bio-Techne Total Stockholders Equity?

Bio-Techne's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $2,014 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Bio-Techne's Book Value per Share for the quarter that ended in Mar. 2024 was $12.79. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Bio-Techne's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.25.

Bio-Techne Total Stockholders Equity Historical Data

The historical data trend for Bio-Techne's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Total Stockholders Equity Chart

Bio-Techne Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,165.59 1,381.19 1,562.97 1,701.77 1,966.52

Bio-Techne Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,889.69 1,966.52 1,997.75 1,963.56 2,014.38

Bio-Techne  (NAS:TECH) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Bio-Techne's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(2014.375-0)/157.554
=12.79

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Bio-Techne's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(12.978 + 481.752) / 2014.375
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne (Bio-Techne) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Total Stockholders Equity
Comparable Companies
INCY UTHR RPRX SRPT BMRN BGNE ROIV LEGN CERE PCVX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
TE1:Germany T1CH34:Brazil
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Website
https://www.bio-techne.com
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Executives
Roeland Nusse director 473 TENNESSEE, PALO ALTO CA 94306
William Geist officer: PRESIDENT, PROTEIN SCIENCES 900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth director, officer: Chief Executive Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Robert V Baumgartner director 5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
Kim Kelderman officer: Pres. Diagnostics & Genom 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor officer: SVP Biotech 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel officer: Chief Financial Officer 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan director C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Alpna Seth director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Julie L Bushman director 185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Randolph C Steer director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413